霍奇金淋巴瘤治疗前维生素D缺乏与无进展生存和总生存受损相关
维生素D缺乏者无进展生存和总生存均显著受损,且为独立预后因素;体外和动物实验提示补充维生素D可增强化疗敏感性。
要点
- 维生素D缺乏者10年无进展生存和总生存分别降低17.6%和11.1%。
- 维生素D状态是独立预后因素,补充可能增强化疗敏感性。
核心结论
- 治疗前维生素D缺乏是霍奇金淋巴瘤患者无进展生存和总生存受损的独立预测因素。
研究设计与样本
- 研究纳入德国霍奇金研究组临床试验HD7、HD8和HD9的351例前瞻性治疗患者,检测治疗前维生素D水平并与临床结局相关分析。
- 另进行体外霍奇金淋巴瘤细胞系实验和异种移植动物模型实验。
主要发现
- 复发/难治患者较匹配的无复发对照更常见维生素D缺乏(中位基线维生素D 21.4 nmol/L vs 35.5 nmol/L;缺乏比例68% vs 41%;P < .001)。
- 维生素D缺乏者无进展生存受损(10年差异17.6%;95% CI 6.9%至28.4%;HR 2.13;95% CI 1.84至2.48;P < .001)。
- 维生素D缺乏者总生存受损(10年差异11.1%;95% CI 2.1%至20.2%;HR 1.82;95% CI 1.53至2.15;P < .001),结果在各试验和治疗组中一致。
- 体外实验显示生理剂量骨化三醇联合化疗增强抗增殖效应;动物模型显示补充胆钙化醇较单用维生素D或化疗降低肿瘤生长速率。
临床怎么用
- 建议在未来随机临床试验中纳入维生素D筛查和补充,以明确维生素D补充治疗在霍奇金淋巴瘤中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Vitamin D deficiency is described as a modifiable risk factor for the incidence of and mortality in many common cancers; however, data in Hodgkin lymphoma (HL) are lacking. PATIENTS AND METHODS: We thus performed a study measuring pretreatment vitamin D levels in prospectively treated patients with HL and correlated this with clinical outcomes. A total of 351 patients from the German Hodgkin Study Group clinical trials (HD7, HD8, and HD9) were included. RESULTS: Fifty percent of patients were vitamin D deficient (< 30 nmol/L) before planned chemotherapy. Pretreatment vitamin D deficiency was more common in relapsed/refractory patients than matched relapse-free controls (median baseline vitamin D, 21.4 nmol/L v 35.5 nmol/L; proportion with vitamin D deficiency, 68% v 41%; P < .001). Vitamin D-deficient patients had impaired progression-free survival (10-year difference, 17.6%; 95% CI, 6.9% to 28.4%; hazard ratio, 2.13; 95% CI, 1.84 to 2.48; P < .001) and overall survival (10-year difference, 11.1%; 95% CI, 2.1% to 20.2%; hazard ratio, 1.82; 95% CI, 1.53 to 2.15; P < .001), consistent across trials and treatment groups. We demonstrated that vitamin D status is an independent predictor of outcome and hypothesized that vitamin D status might be important for the chemosensitivity of HL. We subsequently performed experiments supplementing physiologic doses of vitamin D (calcitriol) to cultured HL cell lines and demonstrated increased antiproliferative effects in combination with chemotherapy. In an HL-xenograft animal model, we showed that supplemental vitamin D (dietary supplement, cholecalciferol) improves the chemosensitivity of tumors by reducing the rate of tumor growth compared with vitamin D or chemotherapy alone. CONCLUSION: On the basis of our clinical and preclinical findings, we encourage that vitamin D screening and replacement be incorporated into future randomized clinical trials to properly clarify the role of vitamin D replacement therapy in HL.
引用
- Borchmann S, Cirillo M, Goergen H, et al. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. J Clin Oncol. 2019. PMID: 31622132. doi:10.1200/JCO.19.00985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。